CYBIN INC

NYSE: CYBN (Cybin Inc.)

Kemas kini terakhir: 28 May, 12:06PM

7.95

-0.39 (-4.68%)

Penutupan Terdahulu 8.34
Buka 8.27
Jumlah Dagangan 328,415
Purata Dagangan (3B) 260,418
Modal Pasaran 167,084,352
Harga / Buku (P/B) 1.07
Julat 52 Minggu
4.81 (-39%) — 13.88 (74%)
Tarikh Pendapatan 10 Feb 2022
EPS Cair (TTM) -3.62
Jumlah Hutang/Ekuiti (D/E MRQ) 0.08%
Nisbah Semasa (MRQ) 12.60
Aliran Tunai Operasi (OCF TTM) -100.89 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -59.45 M
Pulangan Atas Aset (ROA TTM) -44.06%
Pulangan Atas Ekuiti (ROE TTM) -57.49%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Cybin Inc. - -

AISkor Stockmoo

-0.1
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 1.5
Osilator Teknikal 2.0
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CYBN 167 M - - 1.07
LCTX 185 M - - 2.03
PLX 126 M - 31.60 2.78
ANRO 65 M - - 0.470
SER 60 M - 1.78 35.16
ATNM 57 M - - 1.48

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 238.24%
% Dimiliki oleh Institusi 48.73%

Pemilikan

Nama Tarikh Syer Dipegang
Deep Track Capital, Lp 31 Mar 2025 1,529,987
Rosalind Advisors, Inc. 31 Mar 2025 810,918
Acorn Capital Advisors, Llc 31 Mar 2025 734,394
Sphera Funds Management Ltd. 31 Mar 2025 527,222
Ikarian Capital, Llc 31 Mar 2025 397,175
Dcf Advisers, Llc 31 Mar 2025 202,000
Knott David M Jr 31 Mar 2025 66,880
Advisorshares Investments Llc 31 Mar 2025 60,383

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
13 Jun 2025 Pengumuman Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
12 Jun 2025 Pengumuman Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
11 Jun 2025 Pengumuman Cybin to Participate in the 2025 Psychedelic Science Conference
03 Jun 2025 Pengumuman Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
22 May 2025 Pengumuman Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
20 May 2025 Pengumuman Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
15 May 2025 Pengumuman Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
14 May 2025 Pengumuman Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
08 May 2025 Pengumuman Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
01 May 2025 Pengumuman Cybin to Participate at the 28th Annual Milken Institute Global Conference
23 Apr 2025 Pengumuman Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
21 Apr 2025 Pengumuman Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
Papar semua
9.359.358.638.637.907.907.187.186.466.46May 28May 28May 29May 29May 30May 30Jun 2Jun 2Jun 3Jun 3Jun 4Jun 4Jun 5Jun 5Jun 6Jun 6

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.8000.8000.6000.6000.4000.4000.2000.2000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda